Trial site
Fachaerztliche Gemeinschaftspraxis fuer Dermatologie Und Venerologie Allergologie Umweltmedizin Lasermedizin GbR
Blankenfelde-Mahlow, 15831, GermanyNot linked to an institution yet
- 19running trials
- 14closed trials
The trials here
What the 33 trials at this site are about, from their registry records.
- Phase
- Phase 318 trials
- Phase 210 trials
- Phase 12 trials
- Phase 42 trials
- Phase 2/31 trial
- Status
- Active, not recruiting15 trials
- Completed14 trials
- Recruiting3 trials
- Not yet recruiting1 trial
- Lead sponsor
- AbbVie6 trials
- Janssen Research & Development, LLC4 trials
- Sanofi4 trials
- Alumis Inc2 trials
- MoonLake Immunotherapeutics AG2 trials
- and 14 more
Running trials
Not yet recruiting
A Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe Psoriasis
NCT07933536· Phase 2· AbbVie· Source
Active, not recruiting
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
NCT07230860· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07225569· Phase 2· Sanofi· Source
Active, not recruiting
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT07277660· Phase 2· UCB Biopharma SRL· Source
Recruiting
A Study of LAD191 in Adults With Hidradenitis Suppurativa
NCT07151937· Phase 2· Almirall, S.A.· Source
Active, not recruiting
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa
2025-520564-17-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Recruiting
A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis
2024-519795-11-00· Phase 2· Apogee Therapeutics Inc.· Source
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967· Phase 3· Bristol-Myers Squibb· Source
Active, not recruiting
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· Phase 3· Alumis Inc· Source
Active, not recruiting
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076· Phase 3· Takeda· Source
Active, not recruiting
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948· Phase 2· Apogee Therapeutics, Inc.· Source
Active, not recruiting
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
NCT06220604· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118· Phase 3· Sanofi· Source
Active, not recruiting
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411· Phase 3· AbbVie· Source
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
NCT06113471· Phase 3· Incyte Corporation· Source
Active, not recruiting
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578· Phase 2/3· Sanofi· Source
Active, not recruiting
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03568318· Phase 3· AbbVie· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error